Last reviewed 2026-04-22 · How we verify

EU-approved Avastin®

Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.

Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients. Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.

At a glance

Mechanism of action

Bevacizumab binds to circulating VEGF, a key signaling protein that promotes angiogenesis (new blood vessel growth). By neutralizing VEGF, the drug inhibits the formation of new blood vessels that tumors require to grow and metastasize. This anti-angiogenic mechanism reduces tumor perfusion and can slow or halt cancer progression.

Approved indications

• Metastatic colorectal cancer
• Metastatic non-small cell lung cancer
• Metastatic breast cancer
• Glioblastoma
• Metastatic renal cell carcinoma
• Cervical cancer

Common side effects

• Hypertension
• Proteinuria
• Hemorrhage (all grades)
• Thromboembolism
• Gastrointestinal perforation
• Wound healing complications
• Fatigue
• Diarrhea

Key clinical trials

• Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers (PHASE1)
• A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
• A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers (PHASE1)
• A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers (PHASE1)
• Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.